    Jerome Zeldis | Celgene Corporation | ZoomInfo.com 



MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors | Business Wire


























































MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the 
      Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to 
      its Board of Directors




Renown Drug Developer Becomes MetaStat’s Chairman of the Board






May 08, 2017 09:46 AM Eastern Daylight Time



BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology 
      company focused on the development and commercialization of companion 
      diagnostics and anti-metastatic therapeutics in the novel cancer 
      treatments in drugs, today announced the promotion of Jerome B. Zeldis, 
      M.D., Ph.D. from Vice Chairman to Chairman and the appointment of 
      Douglas A. Hamilton, MetaStat’s President and Chief Executive Officer, 
      to its board of directors in connection with a restructuring of 
      MetaStat’s board.
    


      Dr. Zeldis stated, “MetaStat has an exciting technology platform based 
      on the novel mechanisms that drive cancer metastasis and overcome tumor 
      resistance to certain therapeutics, creating the potential to discover 
      novel cancer drugs. I look forward to working with Doug and the MetaStat 
      team in solidifying our mission to discover and develop truly novel 
      approaches for treating a variety of cancers.”
    

      Mr. Hamilton said, “I am delighted Jerry is leading MetaStat’s Board of 
      Directors and honored to serve on the board with him. We have a shared 
      vision for the future of the Company, seeing multiple opportunities to 
      make significant advances in treating cancer.” Mr. Hamilton continued, 
      “Our driver-based diagnostic biomarkers are also therapeutic targets for 
      the development of anti-metastatic drugs and combination therapies to 
      overcome drug resistance. We plan to leverage our driver-based 
      biomarkers and expand strategic partnerships to unlock opportunities in 
      oncology.”
    

      Please see the company’s current report on Form 8-K filed with the 
      Securities and Exchange Commission on May 8, 2017 for full details on 
      the board restructuring, including the resignations of Messrs. Berman, 
      Goodeve and Bronsther.
    

      Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc., 
      and previously served as Chief Medical Officer of Celgene Corporation 
      and Chief Executive Officer of Celgene Global Health until June 2016. 
      Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz 
      Research Institute and Janssen Research Institute in both clinical 
      research and medical affairs. He currently serves as Chairman of the 
      board of Alliqua and Trek Therapeutics, in addition to board positions 
      at PTC Therapeutics and Soligenix. He was Assistant Professor of 
      Medicine at Harvard Medical School, Associate Professor of Medicine at 
      University of California, Davis, Clinical Associate Professor of 
      Medicine at Cornell Medical School, and Professor of Clinical Medicine 
      at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS 
      degrees from Brown University, and M Phil, MD, and PhD degrees from Yale 
      University. Dr. Zeldis has published 122 peer-reviewed articles and is a 
      named inventor on 43 U.S. patents.
    

      Mr. Hamilton has been President and CEO of MetaStat since June 2015. 
      Previously, Mr. Hamilton served as CFO for SEA Medical Systems and since 
      2007, Partner at New Biology Ventures, a life-sciences incubator 
      accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served 
      as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where 
      he led the company to commercialization and through its successful 
      national markets up-listing. Prior to Javelin, Mr. Hamilton was the CFO 
      and Director of Business Development for PolaRx Biopharmaceuticals (now 
      Teva Pharmaceuticals). Mr. Hamilton held positions at Amgen and Pfizer 
      in clinical research and product development, sales and marketing at 
      Pharmacia Biotechnology (now GE Healthcare Life Sciences), and research 
      at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his 
      honors Bachelor of Science degree from the Department of Medical 
      Genetics at the University of Toronto and his MBA from the Ivey Business 
      School at Western University.
    

About MetaStat, Inc.


      MetaStat is a pre-commercial biotechnology company focused on the 
      discovery, development and commercialization of diagnostics tests that 
      are prognostic for risk of cancer metastasis, companion diagnostics to 
      predict drug response and therapeutics to prevent aggressive cancer from 
      spreading. MetaStat’s driver-based diagnostic and therapeutic discovery 
      platform technology is based on the pivotal role of the Mena protein and 
      its isoforms, a common pathway for the development of metastatic disease 
      and drug resistance in all epithelial-based solid tumors. MetaStat is 
      based in Boston, MA.
    

Forward-Looking Statements


      This press release contains "forward-looking statements" within the 
      meaning of Section 27A of the Securities Act of 1933, as amended, and 
      Section 21E of the Securities Exchange Act of 1934, as amended, and such 
      forward-looking statements are made pursuant to the safe harbor 
      provisions of the Private Securities Litigation Reform Act of 1995. You 
      are cautioned that such statements are subject to a multitude of risks 
      and uncertainties that could cause future circumstances, events or 
      results to differ materially from those projected in the forward-looking 
      statements as a result of various factors and other risks, including 
      those set forth in the company's Form 10-K and its other filings filed 
      with the Securities and Exchange Commission. You should consider these 
      factors in evaluating the forward-looking statements included herein, 
      and not place undue reliance on such statements. The forward-looking 
      statements in this release are made as of the date hereof and the 
      company undertakes no obligation to update such statements.
    


Contacts

      MetaStatRick Pierce, VP617-531-0874rpierce@metastat.com











#Hashtags

#diagnostics
#cancer
#breastcancer





Contacts

      MetaStatRick Pierce, VP617-531-0874rpierce@metastat.com







 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up



















Company News



























 Email Alerts








Home

Company Info

Overview

Leadership Team

Board of Directors

Partnerships and Collaborations

Scientific and Clinical Advisors and Collaborators




Technology

Overview

The Mena Protein Isoforms

Scientific & Clinical Publications & Presentations

Patents and Intellectual Property

Videos




Pipeline

Therapeutics (Rx)

Companion Diagnostics (CDx)

Prognostic Diagnostics (PDx)

MetaSite Breast™
MenaCalc™ Platform





Media Center

Recent News

In The News

Industry News




Investors

News / Events

Company News
In The News
IR Calendar
Email Alerts


Company Information

Profile
Presentations
Leadership Team
IR Contacts
FAQ


Financial Information

Financials
Annual Reports
Proxy
Conference Calls


Stock Information

Quote
Charts
Historical Data


SEC Filings

All SEC Filings
Section 16 Filings


Corporate Governance

Board of Directors
Governance Documents





Contact Us






Investors







News / Events

Company News

In The News

IR Calendar

Email Alerts




Company Information


Financial Information


Stock Information


SEC Filings


Corporate Governance






Home / 
Investors / 
News / Events / 
Company News



Company News


Email Alerts
Tear Sheet
IR Contacts
RSS News Feed



MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors
Download PDF


Renown Drug Developer Becomes MetaStat’s Chairman of the Board

    BOSTON--(BUSINESS WIRE)--
      MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology
      company focused on the development and commercialization of companion
      diagnostics and anti-metastatic therapeutics in the novel cancer
      treatments in drugs, today announced the promotion of Jerome B. Zeldis,
      M.D., Ph.D. from Vice Chairman to Chairman and the appointment of
      Douglas A. Hamilton, MetaStat’s President and Chief Executive Officer,
      to its board of directors in connection with a restructuring of
      MetaStat’s board.
    

      Dr. Zeldis stated, “MetaStat has an exciting technology platform based
      on the novel mechanisms that drive cancer metastasis and overcome tumor
      resistance to certain therapeutics, creating the potential to discover
      novel cancer drugs. I look forward to working with Doug and the MetaStat
      team in solidifying our mission to discover and develop truly novel
      approaches for treating a variety of cancers.”
    

      Mr. Hamilton said, “I am delighted Jerry is leading MetaStat’s Board of
      Directors and honored to serve on the board with him. We have a shared
      vision for the future of the Company, seeing multiple opportunities to
      make significant advances in treating cancer.” Mr. Hamilton continued,
      “Our driver-based diagnostic biomarkers are also therapeutic targets for
      the development of anti-metastatic drugs and combination therapies to
      overcome drug resistance. We plan to leverage our driver-based
      biomarkers and expand strategic partnerships to unlock opportunities in
      oncology.”
    

      Please see the company’s current report on Form 8-K filed with the
      Securities and Exchange Commission on May 8, 2017 for full details on
      the board restructuring, including the resignations of Messrs. Berman,
      Goodeve and Bronsther.
    

      Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc.,
      and previously served as Chief Medical Officer of Celgene Corporation
      and Chief Executive Officer of Celgene Global Health until June 2016.
      Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz
      Research Institute and Janssen Research Institute in both clinical
      research and medical affairs. He currently serves as Chairman of the
      board of Alliqua and Trek Therapeutics, in addition to board positions
      at PTC Therapeutics and Soligenix. He was Assistant Professor of
      Medicine at Harvard Medical School, Associate Professor of Medicine at
      University of California, Davis, Clinical Associate Professor of
      Medicine at Cornell Medical School, and Professor of Clinical Medicine
      at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS
      degrees from Brown University, and M Phil, MD, and PhD degrees from Yale
      University. Dr. Zeldis has published 122 peer-reviewed articles and is a
      named inventor on 43 U.S. patents.
    

      Mr. Hamilton has been President and CEO of MetaStat since June 2015.
      Previously, Mr. Hamilton served as CFO for SEA Medical Systems and since
      2007, Partner at New Biology Ventures, a life-sciences incubator
      accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served
      as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where
      he led the company to commercialization and through its successful
      national markets up-listing. Prior to Javelin, Mr. Hamilton was the CFO
      and Director of Business Development for PolaRx Biopharmaceuticals (now
      Teva Pharmaceuticals). Mr. Hamilton held positions at Amgen and Pfizer
      in clinical research and product development, sales and marketing at
      Pharmacia Biotechnology (now GE Healthcare Life Sciences), and research
      at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his
      honors Bachelor of Science degree from the Department of Medical
      Genetics at the University of Toronto and his MBA from the Ivey Business
      School at Western University.
    

About MetaStat, Inc.


      MetaStat is a pre-commercial biotechnology company focused on the
      discovery, development and commercialization of diagnostics tests that
      are prognostic for risk of cancer metastasis, companion diagnostics to
      predict drug response and therapeutics to prevent aggressive cancer from
      spreading. MetaStat’s driver-based diagnostic and therapeutic discovery
      platform technology is based on the pivotal role of the Mena protein and
      its isoforms, a common pathway for the development of metastatic disease
      and drug resistance in all epithelial-based solid tumors. MetaStat is
      based in Boston, MA.
    

Forward-Looking Statements


      This press release contains "forward-looking statements" within the
      meaning of Section 27A of the Securities Act of 1933, as amended, and
      Section 21E of the Securities Exchange Act of 1934, as amended, and such
      forward-looking statements are made pursuant to the safe harbor
      provisions of the Private Securities Litigation Reform Act of 1995. You
      are cautioned that such statements are subject to a multitude of risks
      and uncertainties that could cause future circumstances, events or
      results to differ materially from those projected in the forward-looking
      statements as a result of various factors and other risks, including
      those set forth in the company's Form 10-K and its other filings filed
      with the Securities and Exchange Commission. You should consider these
      factors in evaluating the forward-looking statements included herein,
      and not place undue reliance on such statements. The forward-looking
      statements in this release are made as of the date hereof and the
      company undertakes no obligation to update such statements.
    

View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005771/en/

      MetaStatRick Pierce, VP617-531-0874rpierce@metastat.com

Source: MetaStat, Inc.

Released May 8, 2017







Site Info

Privacy Policy
Disclaimer
Sitemap
Contact Us
Careers



Investor Quicklinks

IR Overview
News / Events
Investor Presentation
Financial Info
IR Contacts
Stock Info
IR FAQ
SEC Filings



Connect With Us

Email Alerts
RSS



        MetaStat, Inc.27 Drydock Ave., 2nd FloorBoston, MA 02210(617) 531-6500
    

Website by Equisolve













MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. To Chairman Of The Board And Appoints Douglas A. Hamilton, MetaStat's President And CEO To Its Board Of Directors - TheStreet





























































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. To Chairman Of The Board And Appoints Douglas A. Hamilton, MetaStat's President And CEO To Its Board Of Directors






Business Wire




May 8, 2017 9:46 AM EDT













 


















































  MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology company focused on the development and commercialization of companion diagnostics and anti-metastatic therapeutics in the novel cancer treatments in drugs, today announced the promotion of Jerome B. Zeldis, M.D., Ph.D. from Vice Chairman to Chairman and the appointment of Douglas A. Hamilton, MetaStat's President and Chief Executive Officer, to its board of directors in connection with a restructuring of MetaStat's board.  Dr. Zeldis stated, "MetaStat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics, creating the potential to discover novel cancer drugs. I look forward to working with Doug and the MetaStat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers."  Mr. Hamilton said, "I am delighted Jerry is leading MetaStat's Board of Directors and honored to serve on the board with him. We have a shared vision for the future of the Company, seeing multiple opportunities to make significant advances in treating cancer." Mr. Hamilton continued, "Our driver-based diagnostic biomarkers are also therapeutic targets for the development of anti-metastatic drugs and combination therapies to overcome drug resistance. We plan to leverage our driver-based biomarkers and expand strategic partnerships to unlock opportunities in oncology."  Please see the company's current report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2017 for full details on the board restructuring, including the resignations of Messrs. Berman, Goodeve and Bronsther.  Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc., and previously served as Chief Medical Officer of Celgene Corporation and Chief Executive Officer of Celgene Global Health until June 2016. Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical affairs. He currently serves as Chairman of the board of Alliqua and Trek Therapeutics, in addition to board positions at PTC Therapeutics and Soligenix. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University. Dr. Zeldis has published 122 peer-reviewed articles and is a named inventor on 43 U.S. patents.  



 








 










































If you liked this article you might like






Microtest Leaps on Acquisition




TSC Staff

Jun 13, 2001 8:52 AM EDT








































 











Trending


FTC Seen as Set to Block Rite Aid Deal


The 12 Absolutely Cheapest Places to Buy a House in America


It Would Be 'Crazy' to Clean House at Wells Fargo, CEO Says


Tesla CEO Elon Musk: We Are Going to Be in Production Hell for 6 Months











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft


















Jerome B Zeldis











 






add/edit





  
		  








	You are here: Scientific Experts > USA > Celgene Corporation > Zeldis > Jerome B Zeldis
      






Research Topicsthalidomideimmunologic factorsmultiple myelomadexamethasonelocal neoplasm recurrenceantineoplastic combined chemotherapy protocolssurvival rateneoplasmsdermatologic agentsimmunologic adjuvantsnon steroidal anti inflammatory agentsclinical trialsteratogensmaternal exposurepaternal exposurerisk managementantineoplastic agentsdrug induced abnormalitiesfetuspostmarketing product surveillancerisk assessmenterythropoiesismyelodysplastic syndromespulmonary embolismalgorithmsunited states food and drug administrationfactual databaseshalf lifestereoisomerismchronic kidney failureJerome B ZeldisSummaryAffiliation: Celgene CorporationCountry: USAPublications  Lenalidomide in multiple myeloma: current role and future directionsJerome B ZeldisCelgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USAExpert Opin Pharmacother 11:829-42. 2010  A review of the history, properties, and use of the immunomodulatory compound lenalidomideJerome B ZeldisCelgene Corporation, Summit, New Jersey, USAAnn N Y Acad Sci 1222:76-82. 2011  RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomideCarmen P CastanedaGlobal Drug Safety, Celgene Corporation, Summit, New Jersey 07901, USADrug Saf 31:743-52. 2008  Thalidomide as a novel therapeutic agent: new uses for an old productSteve K TeoCelgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USADrug Discov Today 10:107-14. 2005  Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge RetentionNancy A BrandenburgCelgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USADrug Saf . 2017  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniquesXionghu YangGlobal Drug Safety, Celgene Corporation, Summit, New Jersey, USAClin Drug Investig 29:161-71. 2009  Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisNianhang ChenCelgene Corporation, 86 Morris Avenue, Summit, NJ 07091, USAJ Clin Pharmacol 47:1466-75. 2007CollaboratorsSteven K TeoNianhang ChenGondi KumarMohamad HusseinR A KnightNancy A BrandenburgRobert BwireJohn FreemanXionghu YangCarmen P CastanedaPaul SheehanFlorence HounMaria Luisa SalomonCurtis Quigley

 Detail InformationPublications7  Lenalidomide in multiple myeloma: current role and future directionsJerome B ZeldisCelgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USAExpert Opin Pharmacother 11:829-42. 2010..This review describes current data on lenalidomide in myeloma and how the unique properties of lenalidomide may lend its use in new settings, such as maintenance and preventive therapy...  A review of the history, properties, and use of the immunomodulatory compound lenalidomideJerome B ZeldisCelgene Corporation, Summit, New Jersey, USAAnn N Y Acad Sci 1222:76-82. 2011..Several early-stage studies are exploring lenalidomide alone and in combination across different hematological malignancies, solid tumors, and immune-related disorders...  RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomideCarmen P CastanedaGlobal Drug Safety, Celgene Corporation, Summit, New Jersey 07901, USADrug Saf 31:743-52. 2008..The pharmacy audit findings showed compliance with RevAssist was high. Although RevAssist is labour-intensive, time-consuming and costly, it continues to be effective in preventing fetal exposure to lenalidomide...  Thalidomide as a novel therapeutic agent: new uses for an old productSteve K TeoCelgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USADrug Discov Today 10:107-14. 2005..The analogue lenalidomide has shown potential in treating the bone marrow disorders multiple myeloma and myelodysplastic syndrome, and is presently in Phase II and III trials, respectively...  Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge RetentionNancy A BrandenburgCelgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USADrug Saf . 2017..The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages...  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniquesXionghu YangGlobal Drug Safety, Celgene Corporation, Summit, New Jersey, USAClin Drug Investig 29:161-71. 2009....  Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisNianhang ChenCelgene Corporation, 86 Morris Avenue, Summit, NJ 07091, USAJ Clin Pharmacol 47:1466-75. 2007..A 4-hour hemodialysis removed 31% of lenalidomide in the body. Therefore, lenalidomide dose adjustments should be considered for patients with CL(Cr) < 50 mL/min, and the recommendations are given for the starting doses...



 
Labome.Org © 2016 All Rights ResearvedPrinceton, New Jersey 08540, USAlast updated: February 20, 2017 
























 



 PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors 
         










    










 






 











 









PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors

Sep 28, 2012, 08:00 ET
		  		  					
						 from   PTC Therapeutics, Inc. 











 
















































 

 






















































 























 

 

 
 
 
 







Dr. Jerome Zeldis.  (PRNewsFoto/PTC Therapeutics, Inc.)    
									
 Facebook
 Twitter
 Pinterest


PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)    
									
 Facebook
 Twitter
 Pinterest

































 




 




Dr. Jerome Zeldis.  (PRNewsFoto/PTC Therapeutics, Inc.)
 























 




 




PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)
 


 
























 




 





 


SOUTH PLAINFIELD, N.J., Sept. 28, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation in Summit, New Jersey.
(Photo:  http://photos.prnewswire.com/prnh/20120928/NY82971)
(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO) 
"We are honored to welcome Dr. Zeldis to PTC's Board of Directors," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "As an established leader in the development of therapies addressing high unmet medical need, Dr. Zeldis' guidance will be extremely valuable as PTC advances ataluren through the clinical and regulatory approval process."
Dr. Zeldis has been with Celgene since 1997; prior to his current role he served as Senior Vice President of Clinical Research and Medical Affairs. Prior to Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He is currently on the board of the Semorex Corporation, the New Jersey chapter of the Arthritis Foundation and the Castleman's Disease Organization. Dr. Zeldis attended Brown University for a B.A., M.S., followed by Yale University for a M.Phil., M.D., and Ph.D. in molecular biophysics and biochemistry (immunochemistry). He trained in internal medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Zeldis has published 121 peer reviewed articles and 24 reviews, book chapters, and editorials.
"PTC is an innovative company at an exciting juncture in the clinical development of ataluren, an investigational new drug, for nonsense-mediated Duchenne and Beckers muscular dystrophy and cystic fibrosis," said Dr. Zeldis. "I look forward to being a part of the next phase of the company's growth, and to working with PTC to support its broad pipeline in rare disorders, cancer and other areas of high unmet medical need."
About PTC Therapeutics, Inc.PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.
 SOURCE  PTC Therapeutics, Inc.  

RELATED LINKS
http://www.ptcbio.com



  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  
















Oct 22, 2012, 08:00 ET
Preview: PTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever




















Jul 23, 2012, 08:00 ET
Preview: PTC Therapeutics Closes $30 Million Financing








My News


  Release contains wide tables.	  View fullscreen.






 Read More





Jul 18, 2017, 08:00 ET
PTC Therapeutics to Host Conference Call to Discuss Second...








Jul 18, 2017, 08:00 ET
PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to...








Jul 18, 2017, 08:00 ET
PTC Therapeutics Announces Publication of Data from ACT DMD in...











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of DirectorsHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets closedS&P 5002,472.10-3.32 (-0.13%)Dow 3021,830.31+33.76 (+0.15%)Nasdaq6,374.68-7.51 (-0.12%)LISTENWho is the face of pro baseball?Yahoo Finance's Dan Roberts and Myles Udland debate the business of baseballMetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of DirectorsBusiness WireMay 8, 2017ReblogShareTweetShareBOSTON--(BUSINESS WIRE)--MetaStat, Inc. (MTST), a pre-commercial biotechnology company focused on the development and commercialization of companion diagnostics and anti-metastatic therapeutics in the novel cancer treatments in drugs, today announced the promotion of Jerome B. Zeldis, M.D., Ph.D. from Vice Chairman to Chairman and the appointment of Douglas A. Hamilton, MetaStat’s President and Chief Executive Officer, to its board of directors in connection with a restructuring of MetaStat’s board.Dr. Zeldis stated, “MetaStat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics, creating the potential to discover novel cancer drugs. I look forward to working with Doug and the MetaStat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers.”Mr. Hamilton said, “I am delighted Jerry is leading MetaStat’s Board of Directors and honored to serve on the board with him. We have a shared vision for the future of the Company, seeing multiple opportunities to make significant advances in treating cancer.” Mr. Hamilton continued, “Our driver-based diagnostic biomarkers are also therapeutic targets for the development of anti-metastatic drugs and combination therapies to overcome drug resistance. We plan to leverage our driver-based biomarkers and expand strategic partnerships to unlock opportunities in oncology.”Please see the company’s current report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2017 for full details on the board restructuring, including the resignations of Messrs. Berman, Goodeve and Bronsther.Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc., and previously served as Chief Medical Officer of Celgene Corporation and Chief Executive Officer of Celgene Global Health until June 2016. Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical affairs. He currently serves as Chairman of the board of Alliqua and Trek Therapeutics, in addition to board positions at PTC Therapeutics and Soligenix. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University. Dr. Zeldis has published 122 peer-reviewed articles and is a named inventor on 43 U.S. patents.Mr. Hamilton has been President and CEO of MetaStat since June 2015. Previously, Mr. Hamilton served as CFO for SEA Medical Systems and since 2007, Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where he led the company to commercialization and through its successful national markets up-listing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals (now Teva Pharmaceuticals). Mr. Hamilton held positions at Amgen and Pfizer in clinical research and product development, sales and marketing at Pharmacia Biotechnology (now GE Healthcare Life Sciences), and research at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.About MetaStat, Inc.MetaStat is a pre-commercial biotechnology company focused on the discovery, development and commercialization of diagnostics tests that are prognostic for risk of cancer metastasis, companion diagnostics to predict drug response and therapeutics to prevent aggressive cancer from spreading. MetaStat’s driver-based diagnostic and therapeutic discovery platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease and drug resistance in all epithelial-based solid tumors. MetaStat is based in Boston, MA.Read MoreForward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K and its other filings filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005771/en/ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextAT&T executives to run combined company after Time Warner dealReutersEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredTesla's Musk hands over first Model 3 electric cars to early buyersReutersMeg Whitman's out. Will GE chief executive take over Uber?SiliconBeatWind Projects in Peril as Indian States Rethink PurchasesBloombergDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredLoan move looms as Bayern plan to keep SanchesOmnisportAnthony Scaramucci's wife reportedly filed for divorce because he was 'hell-bent' on joining TrumpBusiness InsiderMainstream Model 3 holds promise _ and peril _ for TeslaAssociated PressThis Will Be In Everyone's Household By 2020Banyan HillSponsoredThe 'two pizza rule' is a secret to productive meetings that helped Amazon CEO Jeff Bezos become one of the world's richest menBusiness InsiderChevron and Exxon Mobil have a tough path ahead: NYSE traderYahoo Finance VideoStocks mixed after heavy earnings weekCardiologist: 3 Foods You Should Quit ImmediatelyGundry MDSponsoredThe real reason overseas manufacturing is coming to AmericaYahoo FinanceTrump to cops: 'Please don't be too nice' while arresting 'thugs,' and don't worry about their heads when you toss them in the 'paddy wagon'Business InsiderChrissy Teigen Is ‘So Happy’ Donald Trump Blocked Her on TwitterKing Kong: This girl is an ugly mut !!!  I'd block her if I was on twitter too !!!Join the Conversation1 / 5212













News on Jerome B. Zeldis


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology















                                Person                            


                                    Jerome B. Zeldis                                    ▼





                                Topic                            


                                    All Topics                                    ▼








Organizations

                                Find news about organizations
                            





Alumni

                                Find news on alumni of any org
                            





Industries

                                Find news on a particular market
                            





Your Contacts

                                Find news on your contacts
                            








Sign up for free daily alerts on this feed:











By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


















Follow




                            Change Feed
                        


Jerome B. Zeldis











Jerome B. Zeldis is no longer serving in their board position at Kalytera Therapeutics, Inc.


                                May 30, 2017                                 • 
                                RelSci Data Update                            










Kalytera Announces Changes to its Board of Directors


                                May 26, 2017                                 • 
                                GlobeNewswire                            


                                  ... its Board of Directors. Kalytera also announced the resignations of Jerome B. Zeldis, M.D., Ph.D., Director, and David Stefansky, Chairman. "We are grateful to Dr. ...
                                









MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat's President and CEO to its Board of Directors


                                May 8, 2017                                 • 
                                Business Wire                            


                                  ... novel cancer treatments in drugs, today announced the promotion of Jerome B. Zeldis, M.D., Ph.D. from Vice Chairman to Chairman and the appointment of Douglas ...
                                









Sorrento and Wildcat Announce Resolution


                                March 20, 2017                                 • 
                                PR Newswire                            


                                  ... 4 audit firm, Deloitte, and enhanced its senior executive team. Dr. Jerome Zeldis, MD, PhD, former Chief Medical Officer at Celgene Corporation, has been appointed ...
                                









Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies


                                December 1, 2016                                 • 
                                PR Newswire                            


                                  ... and we are excited to further its development in the clinic," said Dr.�Jerome Zeldis,�Chief Medical Officer of Sorrento Therapeutics and President�of TNK Therapeutics. Dr.�Zeldis�added, "We ...
                                









A drug company on a 'mission of affordability'


                                November 4, 2016                                 • 
                                The Washington Post                            


                                  ... Jerome Zeldis remembers how he felt when he heard about the $84,000 price ...
                                









Bionor H1 2016 Interim Financial Report


                                August 23, 2016                                 • 
                                Thomson Reuters ONE                            


                                  ... on 6 June 2016. Board members Benedicte Fossum, Kirsten Drejer and Jerome B. Zeldis resigned from the Board on 28 April 2016 - On 26 ...
                                









Bionor Q1 2016 Interim Financial Report


                                May 11, 2016                                 • 
                                Thomson Reuters ONE                            


                                  ... acting CEO - Three board members, Benedicte Fossum, Kirsten Drejer and Jerome B. Zeldis resigned from the Board on 28 April 2016. Financial guidance for ...
                                









MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors


                                April 27, 2016                                 • 
                                Business Wire                            


                                  ... (OTCQB:MTST), a molecular diagnostic company, today announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as Vice Chairman of the company's Board of ...
                                









BioSig Technologies, Inc. Issues Special Letter to Shareholders


                                December 9, 2015                                 • 
                                Marketwired                            


                                  ... a banner year in strengthening our already leading Board of Directors. Dr. Jerome Zeldis, current Chief Medical Officer of Celgene, Inc. (NASDAQ:CELG), joined in April ...
                                









Kalytera Therapeutics Appoints Dr. Jerome Zeldis to Board of Directors


                                December 1, 2015                                 • 
                                Marketwired                            


                                  ... has appointed Jerome B. Zeldis, M.D., Ph.D., to its Board of Directors. Dr. Zeldis serves as the Chief Medical Officer of Celgene Corporation (Nasdaq: CELG). ...
                                









Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board


                                October 8, 2015                                 • 
                                Business Wire                            


                                  ... Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. Dr. Zeldis is noted for his exceptional and successful experience in drug development. ...
                                









BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board of Directors


                                April 9, 2015                                 • 
                                Marketwired                            


                                  ... BioSig Technologies (OTCQB: BSGM), today announced that Dr. Jerome B. Zeldis has joined the Company's Board of Directors, effective immediately. Dr. ...
                                









Idenix CEO elected to board of PTC Therapeutics a day after news of Merck sale


                                June 11, 2014                                 • 
                                Boston Business Journal                            


                                  ... Also reelected to the board Tuesday was PTC's CEO, Stuart Peltz, and Jerome Zeldis, CEO of Celgene Global Health. PTC is one of three biotechs ...
                                









BIO Reveals Program for 2013 BIO Convention in China


                                October 31, 2013                                 • 
                                Business Wire                            


                                  ... China Country President, Shire; Ko-Chung Lin, PhD, Founder & CEO, Pharmaessentia; Jerry Zeldis, PhD, Chief Executive Officer, Celgene Global Health and Chief Medical Officer, Celgene ...
                                









Healthcare Companies in the News for July 8 - Alliqua, Inc., Derma Sciences, MiMedx, Integra LifeSciences, Oculus Innovative.CM Derma Sciences Inc.


                                July 8, 2013                                 • 
                                PR Newswire                            


                                  ... by group of Alliqua ' s management and board of directors, including Jerome Zeldis, Dave Johnson, David Stefansky, Joseph Leone and Kenneth Pearsen. Dr. Zeldis, ...
                                









Alliqua Raises $3 Million in 2nd Quarter of 2013, Led by Members of Management and its Board of Directors


                                July 8, 2013                                 • 
                                PR Newswire                            


                                  ... by group of Alliqua ' s management and board of directors, including Jerome Zeldis, Dave Johnson, David Stefansky, Joseph Leone and Kenneth Pearsen. Dr. Zeldis, ...
                                









Letter from Alliqua CEO, Dave Johnston, to Shareholders


                                March 7, 2013                                 • 
                                PR Newswire                            


                                  ... on our already experienced board of directors through the appointment of Dr. Jerry Zeldis as Chairman. Jerry continues to serve as the chief medical officer ...
                                









Letter from Alliqua CEO, Dave Johnston, to Shareholders


                                March 7, 2013                                 • 
                                PR Newswire                            


                                  ... on our already experienced board of directors through the appointment of Dr. Jerry Zeldis as Chairman. Jerry continues to serve as the chief medical officer ...
                                







Related News Feeds






Trek Therapeutics







Alumni of Brown University







Jerome B. Zeldis

























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 






Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!


Start My Free Trial  ➤










 Industry:




 Select a Topic:



 Keyword:



Go  ➤









 Find an Organization:






 Select a Topic:




 Keyword:




Go  ➤









 Find a Person:






 Select a Topic:




 Keyword:




Go  ➤









 Name of a School:







 Or Name of an Organization:









 Select a Topic:




 Keyword:




Go  ➤








Thank you. You are now subscribed.Please wait for the page to refresh...










You are now subscribed to this feed.










You have unsubscribed to this feed.










Thank you. You can now subscribe to more RelSci news feeds.










 To subscribe to more than one feed, please enter a password.




 Please confirm your password



Go  ➤








You've found a premium RelSci Pro feature!



Follow News On Your Contacts

Upgrade to RelSci Pro now to easily sync your contacts and stay in the know on the news about the people important to you.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now








You've found a premium RelSci Pro feature!



Search News On Keywords

Curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now













Industries

                        Find news on a particular market
                    





People

                        Find news about people
                    





Organizations

                        Find news about organizations
                    





Alumni

                        Find news on alumni of any org
                    





Your Contacts

                        Find news on your contacts
                    












                Free Daily Alerts
            


                Sign up for free daily alerts on this feed
            




Sign Up ➤

                    By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions




                Already have an account?  Click here to login.















Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤













